I'm LongbridgeAI, I can summarize articles.Pyxis Oncology (PYXS.US) surged more than 16% during regular trading to $1.64.
The company reported updated Phase I trial results for MICVO in previously treated patients with recurrent or metastatic head and neck cancer, showing a confirmed response rate of 39%, median progression-free survival of 6.7 months and median duration of response of 9.2 months among 33 second-line or later patients.
Pyxis Oncology said clinical activity was consistent across patient subgroups with a manageable safety profile, noting the data may support its planned mid-2027 launch of the global Phase III Headliner trial.
Separately, the company narrowed its third-quarter net loss to $19.98 million. Previously disclosed MICVO monotherapy data in advanced head and neck cancer showed a confirmed response rate of 36% and median progression-free survival of 6.2 months.
Based on public media reports. AI-generated; not investment advice.
